Render Target: STATIC
Render Timestamp: 2024-12-20T11:17:30.522Z
Commit: f2d32940205a64f990b886d724ccee2c9935daff
XML generation date: 2024-12-17 23:02:09.337
Product last modified at: 2024-12-18T09:00:10.624Z
Cell Signaling Technology Logo
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

Mast Cell Chymase/CMA1 (F6S4Q) Rabbit mAb #18992

Filter:
  • IHC

    Supporting Data

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa)
    Source/Isotype Rabbit IgG
    Application Key:
    • IHC-Immunohistochemistry 
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    Application Dilution
    Immunohistochemistry (Paraffin) 1:50 - 1:200

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    Mast Cell Chymase/CMA1 (F6S4Q) Rabbit mAb recognizes endogenous levels of total mast cell chymase/CMA1 protein.

    Species Reactivity:

    Human

    The antigen sequence used to produce this antibody shares 100% sequence homology with the species listed here, but reactivity has not been tested or confirmed to work by CST. Use of this product with these species is not covered under our Product Performance Guarantee.

    Species predicted to react based on 100% sequence homology:

    Dog

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Thr195 of human mast cell chymase/CMA1 protein.

    Background

    Mast cell chymase, also known as chymase 1 (CMA1), is one of the major proteases expressed and secreted by mast cells (1). CMA1 is found in cytoplasmic granules before it is released. It converts angiotensin I to angiotensin II and is the major enzyme responsible for doing so in the heart (2). CMA1 can promote pathogenesis of chronic obstructive pulmonary disease (COPD) by inducing TNF-α in lung macrophages (3). CMA1 activity is also implicated in fibrosis in various tissues (4). In COVID-19 patients, CMA1-positive mast cells are significantly elevated, and CMA1 levels are associated with disease severity (5,6). In gastric cancer, CMA1 has been proposed as a prognostic marker, with high expression associated with poor overall survival and with high levels of tumor-infiltrating lymphocytes (TILs) (7).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.